CureVac Shareholders Face Final Deadline in BioNTech Takeover

CureVac NL0015436031

Time is running out for investors in CureVac as the company’s independence draws to a close. The German biopharmaceutical firm, once celebrated as a promising contender in the global vaccine race, is now being fully integrated into its Mainz-based competitor BioNTech. Shareholders have only days remaining to participate in the acquisition before the company’s stock is delisted from public markets.

The transaction is structured as a pure share exchange, with CureVac stockholders receiving 0.05363 BioNTech shares for each of their current holdings. Market participants should note two crucial dates in this process:

• Tuesday, December 2, 2025 (6:00 PM Eastern Time): The operational cutoff for tendering shares
• Wednesday, Read more...